ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 230 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $71,700 | -66.4% | 13,156 | -58.6% | 0.01% | -64.3% |
| Q2 2023 | $213,405 | -31.8% | 31,804 | -10.3% | 0.01% | -26.3% |
| Q1 2023 | $313,059 | +80.7% | 35,454 | +56.3% | 0.02% | +111.1% |
| Q4 2022 | $173,260 | -76.3% | 22,678 | -77.9% | 0.01% | -65.4% |
| Q3 2022 | $732,000 | -3.9% | 102,816 | +9.1% | 0.03% | +18.2% |
| Q2 2022 | $762,000 | -62.2% | 94,225 | -35.1% | 0.02% | -62.1% |
| Q1 2022 | $2,015,000 | +811.8% | 145,182 | +2137.4% | 0.06% | +866.7% |
| Q3 2021 | $221,000 | -31.2% | 6,489 | -17.3% | 0.01% | -40.0% |
| Q2 2021 | $321,000 | -80.5% | 7,850 | -80.8% | 0.01% | -76.7% |
| Q1 2021 | $1,646,000 | +445.0% | 40,893 | +699.9% | 0.04% | +437.5% |
| Q4 2020 | $302,000 | +357.6% | 5,112 | +274.0% | 0.01% | +166.7% |
| Q3 2020 | $66,000 | +1550.0% | 1,367 | +855.9% | 0.00% | – |
| Q3 2019 | $4,000 | – | 143 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $23,152,516 | 15.55% |
| BERYLSON CAPITAL PARTNERS, LLC | 289,726 | $2,213,507 | 6.45% |
| Matrix Capital Management Company, LP | 11,572,590 | $88,414,588 | 1.69% |
| Pier Capital, LLC | 1,012,401 | $7,734,744 | 1.27% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $229,151,929 | 1.15% |
| Eagle Health Investments LP | 607,860 | $4,644,050 | 1.07% |
| Triatomic Management LP | 130,805 | $999,350 | 0.84% |
| Aristotle Atlantic Partners, LLC | 1,880,567 | $14,367,532 | 0.80% |
| Senator Investment Group LP | 1,000,000 | $7,640,000 | 0.69% |
| ARK Investment Management | 9,201,245 | $70,297,512 | 0.61% |